Sanofi touts reduced death risk in PhIII prostate cancer trial

Sanofi-Aventis touted a 28 percent reduced risk of death and a substantial increase in median overall survival rates among patients taking its prostate cancer drug cabazitaxel in combination with prednisone in a late-stage trial. The drug group achieved an improved median overall survival rate of 15.1 months compared to the 12.7 months registered by patients taking mitoxantrone with prednisone. Researchers also tracked a slate of adverse events, not unusual for advanced...